FUTURE SUPPLY MODELS


explore alternative options like e-commerce manufacturers. “When those market forces are in play and you have a critical lifesaving medication that patients cannot live without, there’s potential for disruption of the traditional methods for dispensing insulin,” he says. “That includes potential for new entrants to the market, like generic manufacturers, and that also gives rise to alternative ways for patients to get that medication.” One such manufacturer, Civica RX, plans to


produce insulins glargine, lispro and aspart, which are interchangeable biologics with Lantus, Humalog and Novolog, respectively, as early as 2024. These insulins will have a recommended price to the consumer of no more than $30 per vial and no more than $55   Debbi Ford. Civica insulins will be available to any hospital, retail or online pharmacy that  recommended price, she adds.


Hurdles to success The biggest barrier to more online pharmacies  says. Patients must continue to build trust in online communication with pharmacists in the absence of an in-person interaction, as has been the case during COVID-19, he explains. Adding to this challenge is the prevalent


black market for insulin, which poses a risk for  Incorrect insulin could mean patients lose the ability to control their blood glucose levels, potentially risking death. A 2020 Journal of the American Medical Association (JAMA) meta-  the far lower prices of illegitimate online sales compared with manufacturer list prices. Pharmacies usually don’t test insulin quality and instead rely on US Pharmacopeia (USP)   that the manufacturer is producing insulin that meets US quality standards and can be prescribed to patients, he adds. Typically, when an illegitimate manufacturer   The only way to combat black market insulin sales is to have a testing programme that would randomly test some of the insulin that pharmacies are selling to ensure it meets standards, he notes.  barriers in online insulin sales, moving outside traditional models of medication purchases could prove a tall order. “Most individuals that are utilising insulin already have a close relationship with a physician and a close  “But things could change.”


Clinical Trial Supply Handbook | 51


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56